MDLA yields 5.88% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 1
Combined, MDLA + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of MDLA + ABBV for your $10,000?
Medallia, Inc. provides an enterprise Software-as-a-Service platform in North America, Europe, the Middle East, Africa, and internationally. The company's platform utilizes deep learning-based artificial intelligence technology to analyze structured and unstructured data from signal fields in human, digital, and Internet of Things interactions. It offers products for enterprises to capture signals, including Medallia Conversations, Medallia Crowdicity, Medallia Digital, Medallia Employee Ideas, Medallia LivingLens, Medallia Social, and Medallia Zingle; and analytics, insights, and artificial intelligence products, such as Medallia Predictive and Prescriptive Analytics, Medallia Theme Explorer/Text Analytics, Journey Analytics, and CX360. The company also provides insights on customer experience within the organization to take action comprising Medallia Applications, Medallia Mobile, Medallia Voices, and Org Sync. In addition, it offers professional services, which include managed, implementation, and other services. The company serves retail, technology, manufacturing, financial services, insurance, and hospitality industries. Medallia, Inc. was founded in 2000 and is headquartered in San Francisco, California.
Full MDLA Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.